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Identity 
Other names: ARHE, Rho8, RhoE, memB 




According to Entrez-Gene, RND3 gene maps to 
NC_000002.11 in the region between 151324709 and 
151344180. According to Spidey (mRNA to genomic 
sequence alignment tool, 
http://www.ncbi.nlm.nih.gov/spidey), RND3 has 6 
exons, the sizes being 100, 190, 88, 110, 135, 2047. 
Protein 
Description 
RND3 encodes a 26 kDa, 229 amino acids small 
GTPase protein that belongs to the Rho family of Ras
GTPases superfamily. RND3 is a novel and unusual 
member of the Rho family because its activity is not
controlled by two different reactions: the GDP/GTP 
exchange and the GTP-hydrolysis. So it is unable to 
hydrolyze GTP and is resistant towards GAP activity. 
They possess extended chains at both termini and four 
amino acids are responsible for RND3 GTPase 
deficiency: Ser32, Gln33, Ser79 and Ser81. And 
mutations of these codons in ras genes (Gly12, Gly13, 
Ala59 and Gln61) are responsible for Ras-mediated 
malignant transformation. The structure also implicated 
that it may also make the GTP-bound conformation of 
switch II stabe and could prevent conformational 
changes required during hydrolysis. 
Expression 
RND3 expression is highly regulated in response to 
multiple different stimulies and conditions. 
At transcription, RND3 could be directly regulated by 
many transcriptional factors, including P53, HIF-1a, 
Foxd3, NF-KB, etc. RND3 mRNA and protein levels 
was up-regulated upon DNA damage-inducing stimuli 
including chemotherapeutic agents and ultraviolet (UV) 
irradiation. The response to genetoxic agents is 
mediated by p53, which binds specifically to the RND3 
promoter and regulates RND3 expression while UV-
induced RND3 up-regulation in keratinocytes does not 
depend on p53 status.  
So there must be other DNA damage-induced 
transcription factors to stimulate RND3 transcription. 
For example, NF-kB could induce RND3 expression in 
prostate cancer cells. Hypoxia-inducible factor (HIF)-1 
can increase RND3 protein levels, thereby promotes 
epithelial to mesenchymal transition in gastric cancer 
cells under hypoxic conditions. The induced RND3 
expression represents a pivotal cellular adaptive 
response to hypoxia with implications in gastric cancer 
cell EMT and invasion. In addition, mutant B-Raf 
promotes migration and invasion through inducing 
RND3 expression in melanoma cells. FOXD3 was 
proved to be recruited to the RND3 promoter and 
downregulated RND3 expression at the mRNA and 
protein levels, thus downregulates migration and 
invasion in melanoma cells. The mTOR pathway is 
responsible for the increased expression of RND3 in 
subependymal giant cell astrocytomas and rare brain 
tumours where the mTOR inhibitors TSC1 or TSC2 are 
mutated. The TGF-b pathway is also involved in the 
RND3 expression since the TGF-b family member 
MIC-1/GDF15 could reduce the RND3 expression in 
prostate cancer cells. 
At post-transcription, RND3 mRNA could also be a 
target of the miRNAs. Mir-200b directly 
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downregulated the expression of RND3 at the mRNA 
and protein levels, promoted expression of the 
downstream protein cyclin D1 and increased S-phase 
entry in HeLa cells. There is also study showing that 
RND3 mRNA may be a target of the miR-200c in 
breast cancer cells. MiR-17 targets RND3 tumor 
suppressor gene, promotes cell proliferation, tumor 
growth, cell cycle progression in colorectal carcinoma. 
Localisation 
Located in the membranes, Golgi. 
Function 
RND3 is an atypical member of the Rho family, and 
the study about this molecule is relatively fewer than 
other members of the Rho family. However the recent 
study shows that RND3 could regulate a diverse set of 
biological activities including actin organization, cell 
motility, cell-cycle progression, apoptosis and 
development. 
Role in actin organization 
Many studies on the functions of RND3 have been 
carried out in several cultured cell lines, most of hese 
studies have shown that RND3 could regulate the actin 
cytoskeleton by inducing loss of stress fibres and cell 
rounding. 
Previous studies have shown that RND3 interacts with
p190 RhoGAP and might increase the intrinsic GAP 
activity of p190 RhoGAP for RhoA, thereby reducing 
RhoA-GTP levels. Recent reports have shown that a 
KERRA (Lys-Glu-Arg-Arg-Ala) sequence in their N-
terminus of RND3 could mediate the lipid raft targeting 
of p190 RhoGAP correlated with its activation. RND3 
could also negatively regulates Syx (a RhoA-GEF) 
through interacting with Syx Raf1-like ubiquitin-
related domain thus act as an antagonists of RhoA 
signaling. 
RhoA directly stimulates stress fibres through 
activation of the serine/threonine kinases ROCK1 and
ROCK2. RND3 could interact with the amino-terminal 
region of ROCK1 comprising the kinase domain, so 
RND3 competited with other ROCK1 substrates, such 
as myosin light chain phosphatase, and hence prevent 
stress fibre formation. 
Role in cell cycle regulation 
Many studies have been indicated that RND3 could 
inhibit cell proliferation and these data show that 
RND3 is able to block cell-cycle progression at 
different phases. 
Most studies about cell-cycle shown that RND3 could 
block cell-cycle progression at the G1 phase. The 
mechanism may be that RND3 could decrease the level 
of cyclin D1, reduce Rb phosphorylation and 
transcription of E2F-regulated genes. RND3 blocks the 
phosphorylation of the translational repressor 4E-BP1  
 
in response to extracellular stimuli and also inhibits the 
expression and transcriptional activity of the eIF4E 
target c-Myc. Recent studies show that elevation of 
RND3 expression markedly increased the expression 
level of PTEN and p27 and decreased pAkt level, thus 
inhibit cell-cycle progression. 
RND3 could also block cell-cycle progression at the
G2/M phase. The study in a prostate cancer cell line 
shows that forced RND3 overexpression inhibits the 
expression of CDC2 and cyclin B1 which are essential 
for G2/M transition and induction of G2/M arrest. 
Role in cell apoptosis and survival 
The fuction of RND3 is complex, RND3 can modulate 
cell survival and apoptosis. RND3 can induce apoptosis 
in prostate cancer, esophageal squamous cell carcinoma 
and glioblastoma cell lines. However, in some cancer 
cell lines, high levels of RND3 can decrease apoptosis 
and ShRNA mediated RND3 depletion resulted in an 
increase in apoptosis in response to genotoxic agents or 
UVB. RND3 could increase survival in osteosarcoma 
cells through down-regulate the activity of ROCK1 
which itself can mediate membrane blebbing and 
apoptosis in these cells. RND3 may promote the 
multidrug resistance phenotype of gastric cancer cells 
by decreasing the expression of pro-apoptotic protein 
Bax at post-transcriptional level. 
Role in development 
RND3 plays an important role in the normal 
development, RND3 null mice (RND3 gt/gt) show an 
abnormal body position with profound motor 
impairment and impaired performance in most 
neurobehavioral tests, they are smaller at birth, display 
growth retardation and early postnatal death. There is a 
delay of neuromuscular maturation, a reduction in the 
number of spinal motor neurons, a decrease in the 
number and the total length of the neurites in the RND3 
gt/gt mice. 
Over-expression of RND3 induces neurite-like 
formation through inhibition of the RhoA/ROCK-I 





RND3 expression was dramatically increased in the 
cytoplasm of lung cancer cells compared with 
undetectable expression of RND3 in the adjacent 
nontumoral cells. The cancer-related survival of 
RND3-negative patients are longer than that of RND3-
positive ones. RND3 overexpression may serve as an 
independent marker for cancer-related survival in 
patients with non-small cell lung cancer. 
Overexpression of RND3 was also significantly 
associated with the patients' smoking history and DNA 
copy number changes. 
Prostate cancer 
Oncogenesis 
RND3 mRNA and protein expression were 
significantly reduced in malignant tissue compared to 
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benign samples. Forced RND3 overexpression in a 
prostate cancer cell line inhibits the expression of 
CDC2 and cyclin B1, which induce G2/M arrest, and 
also increases apoptotic cell death. Genetic profiling of 
human prostate cancer cell lines shows that RND3 may 
serve as a potential new molecular marker for assessing 
the metastatic potential of PCa. 
Mammary epithelial tumor 
Oncogenesis 
The expression level of RND3 in cancerous tissues wa  
decreased or absent compared with adjacent normal 
tissues and RND3 could also serve as a negative 
marker in the development and progression of breast 
carcinoma. Exogenously expressed RND3/RND3 
induces the formation of highly sealed tight junctions, 
co-localizes with actin at the cell periphery and iuces 
beta-catenin and ZO-1 to sites of cell-cell contact in 
mammary epithelial tumor cells. 
Human glioblastoma 
Oncogenesis 
Overexpression of RND3 disrupts actin cytoskeleton 
organization, inhibits cell proliferation and induces 
apoptosis in U87 glioblastoma cell line. RND3 reduces 
Rb phosphorylation, cyclin D1 expression and also 
inhibits ERK activation following serum stimulation of 
quiescent U87 cells. 
Esophageal squamous cell carcinoma 
Oncogenesis 
The mRNA and protein expression levels of RND3 was 
significantly downregulated in ESCC (esophageal 
squamous cell carcinoma) tissues and cell lines, RND3 
expression was tightly correlated with differentiation 
degree, clinical staging, and lymph node metastasis of 
the patients with ESCC, but there is no significant 
association between RND3 expression and gender or 
age of the patients with ESCC. Foced downregulation 
of RND3 expression in ESCC cells promoted cell 
proliferation, cell cycle progression, as well as cell 
invasion in vitro, and inhibited cell apoptosis, while 
upregulation of RND3 expression in ESCC cells 
inhibited cell proliferation, arrested cell cycle at G0/G1 
phase, reduced cell invasion, and promoted cell 
apoptosis. RND3 may play an important role in the 
development and progression of ESCC. 
Melanoma 
Oncogenesis 
Many studies have revealed that RND3 overexpressed 
in melanoma cells. B-Raf-mediated up-regulation of 
RND3 appears to participate in the promoting 
melanoma cell invasion by reorganizating the actin  
cytoskeleton and focal adhesions. Upregulation of 
FOXD3 expression inhibits the migration, invasion, 
and spheroid outgrowth of mutant B-RAF melanoma 




Reduced expression of RND3 increases invasiveness 
and metastatic potential in mesenchymal tumor cells 
while ectopic RND3 expression reduced their invasive 
ability in vitro and their metastatic potential in vivo. 
Pancreatic cancer 
Oncogenesis 
A pancreatic cancer-specific expression profiling 




Hepatocellular carcinoma (HCC) is the most common 
type of liver cancer. According to previous study, 
RND3 was down-regulated in HCC cell lines, as 
compared to nontumor liver cells. What's more, the 
patients with low expression of RND3 had a shorter 
survival than those with high expression. Therefore, 
RND3 expression could act as a significant prognostic 
predictor for HCC patients. The SiRNA-mediated 
down-regulation of Rnd3 expression induced a loss of 
E-cadherin and epithelial-mesenchymal transition 
through the up-regulation of the zinc finger E-box 
binding homeobox protein, ZEB2, and the down-
regulation of miR-200b and miR-200c. 
Gastric cancer 
Oncogenesis 
RND3 expression is down-regulated in gastric cancer 
cells and its expression is regulated by histone 
deacetylation, but not DNA methylation at the 
epigenetic levels in gastric cancer cells. However, 
RND3 expression is up-regulated in gastric cancer cells 
under hypoxic conditions. And HIF-1a could up-
regulate RND3 expression through binding a hypoxia-
responsive element (HRE) on the RND3 promoter at 
the transcriptional level. Besides, RND3 is 
overexpressed in the SGC7901 cell line and enhanced 
the resistance of SGC7901 cells to several kinds of 




RND3 is downregulated in colorectal carcinoma (CRC) 
and RND3 expression was significantly lower in CRC 
tissues than in normal tissues and adenomas. Forced 
expression of RND3 can decrease the size of colorectal 
tumor and reduce the CD44 expression and further 
study shows that RND3 could inhibite the  
transcriptional activity of cd44 promoter. MiR-17 also 
plays an important role in CRC carcinogenesis by 
targeting RND3, thus promotes cell proliferation, 
tumour growth and cell cycle progression. However, 
recent study show RND3 could also promote invasion 
and metastasis in human colorectal cancer and it could 
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also serve as an independent prognostic marker in 
addition to the tumor, node, metastasis staging system. 
So the function of RND3 is complex. 
References 
Foster R, Hu KQ, Lu Y, Nolan KM, Thissen J, Settleman J. 
Identification of a novel human Rho protein with unusual 
properties: GTPase deficiency and in vivo farnesylation. Mol 
Cell Biol. 1996 Jun;16(6):2689-99 
Guasch RM, Scambler P, Jones GE, Ridley AJ. RhoE 
regulates actin cytoskeleton organization and cell migration. 
Mol Cell Biol. 1998 Aug;18(8):4761-71 
Nobes CD, Lauritzen I, Mattei MG, Paris S, Hall A, Chardin P. 
A new member of the Rho family, Rnd1, promotes disassembly 
of actin filament structures and loss of cell adhesion. J Cell 
Biol. 1998 Apr 6;141(1):187-97 
Loirand G, Cario-Toumaniantz C, Chardin P, Pacaud P. The 
Rho-related protein Rnd1 inhibits Ca2+ sensitization of rat 
smooth muscle. J Physiol. 1999 May 1;516 ( Pt 3):825-34 
Akashi H, Han HJ, Iizaka M, Nakamura Y. Growth-suppressive 
effect of non-steroidal anti-inflammatory drugs on 11 colon-
cancer cell lines and fluorescence differential display of genes 
whose expression is influenced by sulindac. Int J Cancer. 2000 
Dec 15;88(6):873-80 
Hansen SH, Zegers MM, Woodrow M, Rodriguez-Viciana P, 
Chardin P, Mostov KE, McMahon M. Induced expression of 
Rnd3 is associated with transformation of polarized epithelial 
cells by the Raf-MEK-extracellular signal-regulated kinase 
pathway. Mol Cell Biol. 2000 Dec;20(24):9364-75 
Coleman ML, Sahai EA, Yeo M, Bosch M, Dewar A, Olson MF. 
Membrane blebbing during apoptosis results from caspase-
mediated activation of ROCK I. Nat Cell Biol. 2001 
Apr;3(4):339-45 
Fujita H, Katoh H, Ishikawa Y, Mori K, Negishi M. Rapostlin is 
a novel effector of Rnd2 GTPase inducing neurite branching. J 
Biol Chem. 2002 Nov 22;277(47):45428-34 
Katoh H, Harada A, Mori K, Negishi M. Socius is a novel Rnd 
GTPase-interacting protein involved in disassembly of actin 
stress fibers. Mol Cell Biol. 2002 May;22(9):2952-64 
Tanaka H, Fujita H, Katoh H, Mori K, Negishi M. Vps4-A 
(vacuolar protein sorting 4-A) is a binding partner for a novel 
Rho family GTPase, Rnd2. Biochem J. 2002 Jul 15;365(Pt 
2):349-53 
Zanata SM, Hovatta I, Rohm B, Püschel AW. Antagonistic 
effects of Rnd1 and RhoD GTPases regulate receptor activity 
in Semaphorin 3A-induced cytoskeletal collapse. J Neurosci. 
2002 Jan 15;22(2):471-7 
Cario-Toumaniantz C, Reillaudoux G, Sauzeau V, Heutte F, 
Vaillant N, Finet M, Chardin P, Loirand G, Pacaud P. 
Modulation of RhoA-Rho kinase-mediated Ca2+ sensitization 
of rabbit myometrium during pregnancy - role of Rnd3. J 
Physiol. 2003 Oct 15;552(Pt 2):403-13 
Ishikawa Y, Katoh H, Negishi M. A role of Rnd1 GTPase in 
dendritic spine formation in hippocampal neurons. J Neurosci. 
2003 Dec 3;23(35):11065-72 
Liu T, Bauskin AR, Zaunders J, Brown DA, Pankhurst S, 
Russell PJ, Breit SN. Macrophage inhibitory cytokine 1 
reduces cell adhesion and induces apoptosis in prostate 
cancer cells. Cancer Res. 2003 Aug 15;63(16):5034-40 
Naud N, Touré A, Liu J, Pineau C, Morin L, Dorseuil O, 
Escalier D, Chardin P, Gacon G. Rho family GTPase Rnd2 
interacts and co-localizes with MgcRacGAP in male germ cells. 
Biochem J. 2003 May 15;372(Pt 1):105-12 
Oinuma I, Katoh H, Harada A, Negishi M. Direct interaction of 
Rnd1 with Plexin-B1 regulates PDZ-RhoGEF-mediated Rho 
activation by Plexin-B1 and induces cell contraction in COS-7 
cells. J Biol Chem. 2003 Jul 11;278(28):25671-7 
Wennerberg K, Forget MA, Ellerbroek SM, Arthur WT, Burridge 
K, Settleman J, Der CJ, Hansen SH. Rnd proteins function as 
RhoA antagonists by activating p190 RhoGAP. Curr Biol. 2003 
Jul 1;13(13):1106-15 
Bektic J, Wrulich OA, Dobler G, Kofler K, Ueberall F, Culig Z, 
Bartsch G, Klocker H. Identification of genes involved in 
estrogenic action in the human prostate using microarray 
analysis. Genomics. 2004 Jan;83(1):34-44 
Oinuma I, Ishikawa Y, Katoh H, Negishi M. The Semaphorin 
4D receptor Plexin-B1 is a GTPase activating protein for R-
Ras. Science. 2004 Aug 6;305(5685):862-5 
Villalonga P, Guasch RM, Riento K, Ridley AJ. RhoE inhibits 
cell cycle progression and Ras-induced transformation. Mol 
Cell Biol. 2004 Sep;24(18):7829-40 
Bektic J, Pfeil K, Berger AP, Ramoner R, Pelzer A, Schäfer G, 
Kofler K, Bartsch G, Klocker H. Small G-protein RhoE is 
underexpressed in prostate cancer and induces cell cycle 
arrest and apoptosis. Prostate. 2005 Sep 1;64(4):332-40 
Dovas A, Couchman JR. RhoGDI: multiple functions in the 
regulation of Rho family GTPase activities. Biochem J. 2005 
Aug 15;390(Pt 1):1-9 
Harada A, Katoh H, Negishi M. Direct interaction of Rnd1 with 
FRS2 beta regulates Rnd1-induced down-regulation of RhoA 
activity and is involved in fibroblast growth factor-induced 
neurite outgrowth in PC12 cells. J Biol Chem. 2005 May 
6;280(18):18418-24 
Jaffe AB, Hall A. Rho GTPases: biochemistry and biology. 
Annu Rev Cell Dev Biol. 2005;21:247-69 
Riento K, Totty N, Villalonga P, Garg R, Guasch R, Ridley AJ. 
RhoE function is regulated by ROCK I-mediated 
phosphorylation. EMBO J. 2005 Mar 23;24(6):1170-80 
Riento K, Villalonga P, Garg R, Ridley A. Function and 
regulation of RhoE. Biochem Soc Trans. 2005 Aug;33(Pt 
4):649-51 
Rubenstein NM, Chan JF, Kim JY, Hansen SH, Firestone GL. 
Rnd3/RhoE induces tight junction formation in mammary 
epithelial tumor cells. Exp Cell Res. 2005 Apr 15;305(1):74-82 
Chardin P. Function and regulation of Rnd proteins. Nat Rev 
Mol Cell Biol. 2006 Jan;7(1):54-62 
Dann SG, Thomas G. The amino acid sensitive TOR pathway 
from yeast to mammals. FEBS Lett. 2006 May 
22;580(12):2821-9 
Genovese C, Trani D, Caputi M, Claudio PP. Cell cycle control 
and beyond: emerging roles for the retinoblastoma gene 
family. Oncogene. 2006 Aug 28;25(38):5201-9 
Hurteau GJ, Spivack SD, Brock GJ. Potential mRNA 
degradation targets of hsa-miR-200c, identified using 
informatics and qRT-PCR. Cell Cycle. 2006 Sep;5(17):1951-6 
Lartey J, Gampel A, Pawade J, Mellor H, Bernal AL. 
Expression of RND proteins in human myometrium. Biol 
Reprod. 2006 Sep;75(3):452-61 
Ongusaha PP, Kim HG, Boswell SA, Ridley AJ, Der CJ, Dotto 
GP, Kim YB, Aaronson SA, Lee SW. RhoE is a pro-survival 
p53 target gene that inhibits ROCK I-mediated apoptosis in 
response to genotoxic stress. Curr Biol. 2006 Dec 
19;16(24):2466-72 






Atlas Genet Cytogenet Oncol Haematol. 2013; 17(7)  471 
Tanaka H, Katoh H, Negishi M. Pragmin, a novel effector of 
Rnd2 GTPase, stimulates RhoA activity. J Biol Chem. 2006 
Apr 14;281(15):10355-64 
Aspenström P, Ruusala A, Pacholsky D. Taking Rho GTPases 
to the next level: the cellular functions of atypical Rho 
GTPases. Exp Cell Res. 2007 Oct 15;313(17):3673-9 
Boswell SA, Ongusaha PP, Nghiem P, Lee SW. The protective 
role of a small GTPase RhoE against UVB-induced DNA 
damage in keratinocytes. J Biol Chem. 2007 Feb 
16;282(7):4850-8 
Boureux A, Vignal E, Faure S, Fort P. Evolution of the Rho 
family of ras-like GTPases in eukaryotes. Mol Biol Evol. 2007 
Jan;24(1):203-16 
Gadea G, de Toledo M, Anguille C, Roux P. Loss of p53 
promotes RhoA-ROCK-dependent cell migration and invasion 
in 3D matrices. J Cell Biol. 2007 Jul 2;178(1):23-30 
Guan L, Song K, Pysz MA, Curry KJ, Hizli AA, Danielpour D, 
Black AR, Black JD. Protein kinase C-mediated down-
regulation of cyclin D1 involves activation of the translational 
repressor 4E-BP1 via a phosphoinositide 3-kinase/Akt-
independent, protein phosphatase 2A-dependent mechanism 
in intestinal epithelial cells. J Biol Chem. 2007 May 
11;282(19):14213-25 
Marie-Claire C, Salzmann J, David A, Courtin C, Canestrelli C, 
Noble F. Rnd family genes are differentially regulated by 3,4-
methylenedioxymethamphetamine and cocaine acute 
treatment in mice brain. Brain Res. 2007 Feb 23;1134(1):12-7 
Ogata S, Morokuma J, Hayata T, Kolle G, Niehrs C, Ueno N, 
Cho KW. TGF-beta signaling-mediated morphogenesis: 
modulation of cell adhesion via cadherin endocytosis. Genes 
Dev. 2007 Jul 15;21(14):1817-31 
Poch E, Miñambres R, Mocholí E, Ivorra C, Pérez-Aragó A, 
Guerri C, Pérez-Roger I, Guasch RM. RhoE interferes with Rb 
inactivation and regulates the proliferation and survival of the 
U87 human glioblastoma cell line. Exp Cell Res. 2007 Feb 
15;313(4):719-31 
Püschel AW. GTPases in semaphorin signaling. Adv Exp Med 
Biol. 2007;600:12-23 
Berthold J, Schenkova K, Rivero F. Rho GTPases of the 
RhoBTB subfamily and tumorigenesis. Acta Pharmacol Sin. 
2008 Mar;29(3):285-95 
Chiarugi P, Giannoni E. Anoikis: a necessary death program 
for anchorage-dependent cells. Biochem Pharmacol. 2008 Dec 
1;76(11):1352-64 
Fortier M, Comunale F, Kucharczak J, Blangy A, Charrasse S, 
Gauthier-Rouvière C. RhoE controls myoblast alignment prior 
fusion through RhoA and ROCK. Cell Death Differ. 2008 
Aug;15(8):1221-31 
Heasman SJ, Ridley AJ. Mammalian Rho GTPases: new 
insights into their functions from in vivo studies. Nat Rev Mol 
Cell Biol. 2008 Sep;9(9):690-701 
Heng JI, Nguyen L, Castro DS, Zimmer C, Wildner H, Armant 
O, Skowronska-Krawczyk D, Bedogni F, Matter JM, Hevner R,  
Guillemot F. Neurogenin 2 controls cortical neuron migration 
through regulation of Rnd2. Nature. 2008 Sep 
4;455(7209):114-8 
Klein RM, Spofford LS, Abel EV, Ortiz A, Aplin AE. B-RAF 
regulation of Rnd3 participates in actin cytoskeletal and focal 
adhesion organization. Mol Biol Cell. 2008 Feb;19(2):498-508 
Komander D, Garg R, Wan PT, Ridley AJ, Barford D. 
Mechanism of multi-site phosphorylation from a ROCK-I:RhoE 
complex structure. EMBO J. 2008 Dec 3;27(23):3175-85 
Pinner S, Sahai E. PDK1 regulates cancer cell motility by 
antagonising inhibition of ROCK1 by RhoE. Nat Cell Biol. 2008 
Feb;10(2):127-37 
Roberts PJ, Mitin N, Keller PJ, Chenette EJ, Madigan JP, 
Currin RO, Cox AD, Wilson O, Kirschmeier P, Der CJ. Rho 
Family GTPase modification and dependence on CAAX motif-
signaled posttranslational modification. J Biol Chem. 2008 Sep 
12;283(37):25150-63 
Shurin GV, Tourkova IL, Shurin MR. Low-dose 
chemotherapeutic agents regulate small Rho GTPase activity 
in dendritic cells. J Immunother. 2008 Jun;31(5):491-9 
Ballester-Lurbe B, Poch E, Mocholí E, Guasch RM, Pérez-
Roger I, Terrado J. RhoE is spatiotemporally regulated in the 
postnatal mouse CNS. Neuroscience. 2009 Oct 6;163(2):586-
93 
Bracken CP, Gregory PA, Khew-Goodall Y, Goodall GJ. The 
role of microRNAs in metastasis and epithelial-mesenchymal 
transition. Cell Mol Life Sci. 2009 May;66(10):1682-99 
Glotzer M. Cytokinesis: GAP gap. Curr Biol. 2009 Feb 
24;19(4):R162-5 
Goda T, Takagi C, Ueno N. Xenopus Rnd1 and Rnd3 GTP-
binding proteins are expressed under the control of 
segmentation clock and required for somite formation. Dev 
Dyn. 2009 Nov;238(11):2867-76 
Klein RM, Aplin AE. Rnd3 regulation of the actin cytoskeleton 
promotes melanoma migration and invasive outgrowth in three 
dimensions. Cancer Res. 2009 Mar 15;69(6):2224-33 
Li K, Lu Y, Liang J, Luo G, Ren G, Wang X, Fan D. RhoE 
enhances multidrug resistance of gastric cancer cells by 
suppressing Bax. Biochem Biophys Res Commun. 2009 Feb 
6;379(2):212-6 
Li YH, Ghavampur S, Bondallaz P, Will L, Grenningloh G, 
Püschel AW. Rnd1 regulates axon extension by enhancing the 
microtubule destabilizing activity of SCG10. J Biol Chem. 2009 
Jan 2;284(1):363-71 
Liebig T, Erasmus J, Kalaji R, Davies D, Loirand G, Ridley A, 
Braga VM. RhoE Is required for keratinocyte differentiation and 
stratification. Mol Biol Cell. 2009 Jan;20(1):452-63 
Madigan JP, Bodemann BO, Brady DC, Dewar BJ, Keller PJ, 
Leitges M, Philips MR, Ridley AJ, Der CJ, Cox AD. Regulation 
of Rnd3 localization and function by protein kinase C alpha-
mediated phosphorylation. Biochem J. 2009 Oct 
23;424(1):153-61 
Mori K, Amano M, Takefuji M, Kato K, Morita Y, Nishioka T, 
Matsuura Y, Murohara T, Kaibuchi K. Rho-kinase contributes 
to sustained RhoA activation through phosphorylation of p190A 
RhoGAP. J Biol Chem. 2009 Feb 20;284(8):5067-76 
Shimomura A, Ohama T, Hori M, Ozaki H. 17Beta-estradiol 
induces gastrointestinal motility disorder by decreasing CPI-17 
phosphorylation via changes in rho-family G-protein Rnd 
expression in small intestine. J Vet Med Sci. 2009 
Dec;71(12):1591-7 
Shimono Y, Zabala M, Cho RW, Lobo N, Dalerba P, Qian D, 
Diehn M, Liu H, Panula SP, Chiao E, Dirbas FM, Somlo G, 
Pera RA, Lao K, Clarke MF. Downregulation of miRNA-200c 
links breast cancer stem cells with normal stem cells. Cell. 
2009 Aug 7;138(3):592-603 
Uesugi K, Oinuma I, Katoh H, Negishi M. Different requirement 
for Rnd GTPases of R-Ras GAP activity of Plexin-C1 and 
Plexin-D1. J Biol Chem. 2009 Mar 13;284(11):6743-51 
Villalonga P, Fernández de Mattos S, Ridley AJ. RhoE inhibits 
4E-BP1 phosphorylation and eIF4E function impairing cap-






Atlas Genet Cytogenet Oncol Haematol. 2013; 17(7)  472 
dependent translation. J Biol Chem. 2009 Dec 
18;284(51):35287-96 
Yoshihara Y, De Roo M, Muller D. Dendritic spine formation 
and stabilization. Curr Opin Neurobiol. 2009 Apr;19(2):146-53 
Belgiovine C, Frapolli R, Bonezzi K, Chiodi I, Favero F, Mello-
Grand M, Dei Tos AP, Giulotto E, Taraboletti G, D'Incalci M, 
Mondello C. Reduced expression of the ROCK inhibitor Rnd3 
is associated with increased invasiveness and metastatic 
potential in mesenchymal tumor cells. PLoS One. 2010 Nov 
30;5(11):e14154 
Friedl P, Wolf K. Plasticity of cell migration: a multiscale tuning 
model. J Cell Biol. 2010 Jan 11;188(1):11-9 
Goh LL, Manser E. The RhoA GEF Syx is a target of Rnd3 and 
regulated via a Raf1-like ubiquitin-related domain. PLoS One. 
2010 Aug 25;5(8):e12409 
Nadiminty N, Dutt S, Tepper C, Gao AC. Microarray analysis 
reveals potential target genes of NF-kappaB2/p52 in LNCaP 
prostate cancer cells. Prostate. 2010 Feb 15;70(3):276-87 
Riou P, Villalonga P, Ridley AJ. Rnd proteins: multifunctional 
regulators of the cytoskeleton and cell cycle progression. 
Bioessays. 2010 Nov;32(11):986-92 
Talens-Visconti R, Peris B, Guerri C, Guasch RM. RhoE 
stimulates neurite-like outgrowth in PC12 cells through 
inhibition of the RhoA/ROCK-I signalling. J Neurochem. 2010 
Feb;112(4):1074-87 
Tyburczy ME, Kotulska K, Pokarowski P, Mieczkowski J, 
Kucharska J, Grajkowska W, Roszkowski M, Jozwiak S, 
Kaminska B. Novel proteins regulated by mTOR in 
subependymal giant cell astrocytomas of patients with 
tuberous sclerosis complex and new therapeutic implications. 
Am J Pathol. 2010 Apr;176(4):1878-90 
Wang D, Dubois RN. The role of COX-2 in intestinal 
inflammation and colorectal cancer. Oncogene. 2010 Feb 
11;29(6):781-8 
Xia W, Li J, Chen L, Huang B, Li S, Yang G, Ding H, Wang F, 
Liu N, Zhao Q, Fang T, Song T, Wang T, Shao N. MicroRNA-
200b regulates cyclin D1 expression and promotes S-phase 
entry by targeting RND3 in HeLa cells. Mol Cell Biochem. 2010 
Nov;344(1-2):261-6 
Chen J, Zhou H, Li Q, Qiu M, Li Z, Tang Q, Liu M, Zhu Y, 
Huang J, Lang N, Liu Z, Deng Y, Zhang S, Bi F. Epigenetic 
modification of RhoE expression in gastric cancer cells. Oncol 
Rep. 2011 Jan;25(1):173-80 
Chun KH, Choi KD, Lee DH, Jung Y, Henry RR, Ciaraldi TP, 
Kim YB. In vivo activation of ROCK1 by insulin is impaired in 
skeletal muscle of humans with type 2 diabetes. Am J Physiol 
Endocrinol Metab. 2011 Mar;300(3):E536-42 
Katiyar P, Aplin AE. FOXD3 regulates migration properties and 
Rnd3 expression in melanoma cells. Mol Cancer Res. 2011 
May;9(5):545-52 
Klein RM, Higgins PJ. A switch in RND3-RHOA signaling is 
critical for melanoma cell invasion following mutant-BRAF 
inhibition. Mol Cancer. 2011 Sep 14;10:114 
Li J, Anton ES. Rnd-ing up RhoA activity to link neurogenesis 
with steps in neuronal migration. Dev Cell. 2011 Apr 
19;20(4):409-10 
Mocholí E, Ballester-Lurbe B, Arqué G, Poch E, Peris B, Guerri 
C, Dierssen M, Guasch RM, Terrado J, Pérez-Roger I. RhoE 
deficiency produces postnatal lethality, profound motor deficits 
and neurodevelopmental delay in mice. PLoS One. 2011 Apr 
28;6(4):e19236 
Pacary E, Heng J, Azzarelli R, Riou P et al.. Proneural 
transcription factors regulate different steps of cortical neuron 
migration through Rnd-mediated inhibition of RhoA signaling. 
Neuron. 2011 Mar 24;69(6):1069-84 
Zhou HJ, Li LL, Yue CX, Wei W, Li NJ, Tang QL, Bi F. [The 
effect of RhoE on CD44 promoter and the malignant behaviors 
of colorectal cancer cell]. Sichuan Da Xue Xue Bao Yi Xue 
Ban. 2011 Sep;42(5):589-93 
Zhou J, Li K, Gu Y, Feng B, Ren G, Zhang L, Wang Y, Nie Y, 
Fan D. Transcriptional up-regulation of RhoE by hypoxia-
inducible factor (HIF)-1 promotes epithelial to mesenchymal 
transition of gastric cancer cells during hypoxia. Biochem 
Biophys Res Commun. 2011 Nov 18;415(2):348-54 
Collett GP, Goh XF, Linton EA, Redman CW, Sargent IL. RhoE 
is regulated by cyclic AMP and promotes fusion of human 
BeWo choriocarcinoma cells. PLoS One. 2012;7(1):e30453 
Grise F, Sena S, Bidaud-Meynard A, Baud J, Hiriart JB, Makki 
K, Dugot-Senant N, Staedel C, Bioulac-Sage P, Zucman-Rossi 
J, Rosenbaum J, Moreau V. Rnd3/RhoE Is down-regulated in 
hepatocellular carcinoma and controls cellular invasion. 
Hepatology. 2012 Jun;55(6):1766-75 
Luo H, Dong Z, Zou J, Zeng Q, Wu D, Liu L. Down-regulation 
of RhoE is associated with progression and poor prognosis in 
hepatocellular carcinoma. J Surg Oncol. 2012 Jun 
1;105(7):699-704 
Luo H, Zou J, Dong Z, Zeng Q, Wu D, Liu L. Up-regulated miR-
17 promotes cell proliferation, tumour growth and cell cycle 
progression by targeting the RND3 tumour suppressor gene in 
colorectal carcinoma. Biochem J. 2012 Mar 1;442(2):311-21 
Oinuma I, Kawada K, Tsukagoshi K, Negishi M. Rnd1 and 
Rnd3 targeting to lipid raft is required for p190 RhoGAP 
activation. Mol Biol Cell. 2012 Apr;23(8):1593-604 
Peris B, Gonzalez-Granero S, Ballester-Lurbe B, García-
Verdugo JM, Pérez-Roger I, Guerri C, Terrado J, Guasch RM. 
Neuronal polarization is impaired in mice lacking RhoE 
expression. J Neurochem. 2012 Jun;121(6):903-14 
Ryan KR, Lock FE, Heath JK, Hotchin NA. Plakoglobin-
dependent regulation of keratinocyte apoptosis by Rnd3. J Cell 
Sci. 2012 Jul 1;125(Pt 13):3202-9 
Zhou J, Yang J, Li K, Mo P, Feng B, Wang X, Nie Y, Fan D. 
RhoE is associated with relapse and prognosis of patients with 
colorectal cancer. Ann Surg Oncol. 2013 Jan;20(1):175-82 
This article should be referenced as such: 
Hongwei X, Yucheng Z, Feng B. RND3 (Rho family GTPase 
3). Atlas Genet Cytogenet Oncol Haematol. 2013; 17(7):467-
472. 
